Increased tumor-associated IL-17 predicts improved patient survival. (A-C) Kaplan-Meier curve for overall survival by the levels of IL-17 in 85 patients in stage II-IV (A), stage III (B), and stage IV (C). Samples were divided into 2 groups based on the median levels of IL-17 in tumor ascites (“Statistical calculations”). Survival was significantly increased as a function of IL-17. (D) The levels of IL-17 in different stages were compared.